
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6402630/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	13.9	2,807
2	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	13.9	2,080
3	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 799-808.	13.9	1,915
4	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 1406-1415.	13.9	1,607
5	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 2018, 378, 615-624.	13.9	1,237
6	Antithrombotic Therapy for Venous Thromboembolic Disease. Chest, 2004, 126, 401S-428S.	0.4	1,216
7	Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2013, 368, 699-708.	13.9	1,116
8	Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis. Journal of Clinical Oncology, 2000, 18, 3078-3083.	0.8	691
9	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood, 2014, 124, 1968-1975.	0.6	662
10	Deep vein thrombosis and pulmonary embolism. Lancet, The, 2016, 388, 3060-3073.	6.3	572
11	Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis. Annals of Internal Medicine, 2004, 140, 867.	2.0	539
12	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. New England Journal of Medicine, 2015, 372, 232-240.	13.9	497
13	Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ: British Medical Journal, 1998, 316, 17-20.	2.4	338
14	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study. Blood, 2008, 112, 2242-2247.	0.6	316
15	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. European Heart Journal, 2018, 39, 4208-4218.	1.0	267
16	Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood, 2009, 113, 5314-5322.	0.6	206
17	The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica, 2019, 104, 1277-1287.	1.7	197
18	Plasminogen Activator and Plasminogen Activator Inhibitor I Release during Experimental Endotoxaemia in Chimpanzees: Effect of Interventions in the Cytokine and Coagulation Cascades. Clinical Science, 1995, 88, 587-594.	1.8	182

#	Article	IF	CITATIONS
19	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ: British Medical Journal, 2019, 366, l4363.	2.4	177
20	Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica, 2017, 102, 1494-1501.	1.7	164
21	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis, 2018, 118, 1439-1449.	1.8	154
22	Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine, 2021, 385, 609-617.	13.9	143
23	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematology,the, 2016, 3, e379-e387.	2.2	136
24	Undiagnosed malignancy in patients with deep vein thrombosis. , 1998, 83, 180-185.		133
25	Complete Inhibition of Endotoxin-Induced Coagulation Activation in Chimpanzees with a Monoclonal Fab Fragment against Factor VII/VIIa. Thrombosis and Haemostasis, 1995, 73, 223-230.	1.8	113
26	Contrast Venography, the Gold Standard for the Diagnosis of Deep-Vein Thrombosis: Improvement in Observer Agreement. Thrombosis and Haemostasis, 1992, 67, 08-12.	1.8	107
27	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood, 2020, 136, 1433-1441.	0.6	106
28	Thrombosis: A Major Contributor to Global Disease Burden. Seminars in Thrombosis and Hemostasis, 2014, 40, 724-735.	1.5	103
29	Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2019, 17, 645-656.	1.9	80
30	Use of Oral Glucocorticoids and the Risk of Pulmonary Embolism. Chest, 2013, 143, 1337-1342.	0.4	73
31	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. Chest, 2011, 140, 366-373.	0.4	69
32	The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. British Journal of Haematology, 2001, 113, 553-555.	1.2	68
33	Diagnostic prediction models for suspected pulmonary embolism: systematic review and independent external validation in primary care. BMJ, The, 2015, 351, h4438.	3.0	63
34	Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet, The, 2012, 379, 123-129.	6.3	57
35	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation. Stroke, 2015, 46, 2523-2528.	1.0	57
36	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e228-e236.	2.2	55

HARRY R Büller

#	Article	IF	CITATIONS
37	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. Circulation, 2014, 130, 410-418.	1.6	53
38	Tumor Necrosis Factor Induces von Willebrand Factor Release in Healthy Humans. Thrombosis and Haemostasis, 1992, 67, 623-626.	1.8	48
39	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal, 2019, 40, 1492-1500.	1.0	45
40	The Use of the D-Dimer Test in Combination with Non-Invasive Testing Versus Serial Non-Invasive Testing Alone for the Diagnosis of Deep-Vein Thrombosis. Thrombosis and Haemostasis, 1992, 67, 510-513.	1.8	43
41	Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study. Thrombosis Research, 2018, 166, 54-59.	0.8	42
42	Comparison of Real-Time B-Mode Ultrasonography and Doppler Ultrasound with Contrast Venography in the Diagnosis of Venous Thrombosis in Symptomatic Outpatients. Thrombosis and Haemostasis, 1993, 70, 404-407.	1.8	42
43	The value of lung scintigraphy in the diagnosis of pulmonary embolism. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 173-181.	2.2	37
44	Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation. Chest, 2013, 144, 1839-1847.	0.4	37
45	The diagnostic management of upper extremity deep vein thrombosis: A review of the literature. Thrombosis Research, 2017, 156, 54-59.	0.8	37
46	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Advances, 2020, 4, 5215-5225.	2.5	35
47	Definition of pulmonary embolismâ€related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 1495-1500.	1.9	33
48	Arterial Thromboembolism in CancerÂPatients. JACC: CardioOncology, 2021, 3, 205-218.	1.7	33
49	Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thrombosis Research, 2016, 140, S81-S88.	0.8	31
50	Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal, 2020, 55, 1901697.	3.1	31
51	Diagnostic outcome management study in patients with clinically suspected recurrent acute pulmonary embolism with a structured algorithm. Thrombosis Research, 2014, 133, 1039-1044.	0.8	30
52	Ruling Out Pulmonary Embolism in Primary Care: Comparison of the Diagnostic Performance of "Gestalt" and the Wells Rule. Annals of Family Medicine, 2016, 14, 227-234.	0.9	30
53	Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis. Journal of Clinical Medicine, 2020, 9, 2069.	1.0	30
54	The Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Thrombosis and Haemostasis, 1997, 78, 489-496.	1.8	30

#	Article	IF	CITATIONS
55	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e437-e445.	2.2	29
56	Extended treatment of venous thromboembolism: a systematic review and network meta-analysis. Heart, 2019, 105, 545-552.	1.2	29
57	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Advances, 2020, 4, 6291-6297.	2.5	28
58	Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart. Thrombosis and Haemostasis, 1992, 68, 245-249.	1.8	27
59	Physiological Changes Due to Age. Drugs and Aging, 1994, 5, 20-33.	1.3	26
60	Bleeding Risk in Patients With Atrial Fibrillation. Chest, 2011, 140, 146-155.	0.4	26
61	Safely ruling out deep venous thrombosis in primary care. Annals of Internal Medicine, 2009, 150, 229-35.	2.0	26
62	Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. British Journal of Haematology, 1996, 92, 740-743.	1.2	25
63	Treatment of Venous Thromboembolism. Thrombosis and Haemostasis, 1995, 74, 197-203.	1.8	25
64	Pulmonary embolism at autopsy in cancer patients. Journal of Thrombosis and Haemostasis, 2021, 19, 1228-1235.	1.9	24
65	Randomized Double-Blind, Placebo Controlled Safety Study of a Low Molecular Weight Heparinoid in Patients Undergoing Transurethral Resection of the Prostate. Thrombosis and Haemostasis, 1987, 57, 092-096.	1.8	24
66	The intestinal microbiome potentially affects thrombin generation in human subjects. Journal of Thrombosis and Haemostasis, 2020, 18, 642-650.	1.9	22
67	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thrombosis Research, 2018, 162, 7-14.	0.8	20
68	A New Computerized Impedance Plethysmograph: Accuracy in the Detection of Proximal Deep-Vein Thrombosis in Symptomatic Outpatients. Thrombosis and Haemostasis, 1991, 65, 229-232.	1.8	20
69	Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0228788.	1.1	20
70	Editorial. Cardiovascular Research, 1999, 41, 21-24.	1.8	18
71	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	0.8	18
72	Deep Vein Thrombosis and Fibrinolysis. Thrombosis and Haemostasis, 1991, 66, 426-429.	1.8	17

#	Article	IF	CITATIONS
73	The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism. Health Economics (United Kingdom), 1996, 5, 307-318.	0.8	15
74	A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. Thrombosis Research, 2016, 148, 59-62.	0.8	15
75	Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. European Respiratory Journal, 2017, 50, 1701097.	3.1	15
76	Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2018, 118, 1270-1278.	1.8	15
77	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood, 2013, 122, 211-211.	0.6	15
78	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open, 2017, 7, e015562.	0.8	14
79	Edoxaban for Cancer-Associated Venous Thromboembolism. New England Journal of Medicine, 2018, 379, 93-96.	13.9	14
80	Evaluation of the Khorana, PROTECHT, and $5\hat{a}\in$ SNP scores for prediction of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2021, 19, 2974-2983.	1.9	14
81	Clinical studies with low-molecular-weight heparin(oid)s: An interim analysis. American Journal of Hematology, 1988, 27, 146-153.	2.0	13
82	Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination. Journal of Thrombosis and Thrombolysis, 2000, 9, 263-269.	1.0	13
83	Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. Hematology American Society of Hematology Education Program, 2015, 2015, 125-131.	0.9	12
84	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thrombosis and Haemostasis, 2018, 118, 174-181.	1.8	11
85	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis, 2019, 119, 461-466.	1.8	11
86	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis, 2021, 19, 3008-3017.	1.9	10
87	Alternative diagnoses in patients in whom the GP considered the diagnosis of pulmonary embolism. Family Practice, 2014, 31, 670-677.	0.8	9
88	Evaluation of Once Weekly Subcutaneous Idraparinux Versus Standard Therapy with Heparin and Vitamin K Antagonists in the Treatment of Deep-Vein Thrombosis or Pulmonary Embolism - The Van Gogh Investigators Blood, 2006, 108, 6-6.	0.6	9
89	Changes in perfusion scintigraphy in the first days of heparin therapy in patients with acute pulmonary embolism. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1481-1486.	2.2	8
90	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	1.8	8

#	Article	IF	CITATIONS
91	Implementing Thrombosis Guidelines in Cancer Patients: A Review. Rambam Maimonides Medical Journal, 2014, 5, e0041.	0.4	8
92	Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Heart Rhythm, 2017, 14, 599-605.	0.3	7
93	Development of a standardized definition of pulmonary embolismâ€related death: A crossâ€sectional survey of international thrombosis experts. Journal of Thrombosis and Haemostasis, 2020, 18, 1415-1420.	1.9	7
94	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	0.8	6
95	Pregnancyâ€related venous thromboembolism and HIV infection. International Journal of Gynecology and Obstetrics, 2021, 155, 110-118.	1.0	6
96	Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT) Blood, 2007, 110, 1880-1880.	0.6	6
97	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	0.7	5
98	The Role of a Decision Rule in Symptomatic Pulmonary Embolism Patients with a Non-high Probability Ventilation-perfusion Scan. Thrombosis and Haemostasis, 1997, 78, 794-798.	1.8	5
99	Pharmacological Prevention of Venous Thromboembolism. , 0, , 435-461.		4
100	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thrombosis Research, 2015, 136, S13-S18.	0.8	4
101	Additive Effect of the Combined Administration of Low Molecular Weight Heparin and Recombinant Hirudin on Thrombus Growth in a Rabbit Jugular Vein Thrombosis Model. Thrombosis and Haemostasis, 1994, 72, 377-380.	1.8	4
102	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. Blood, 2018, 132, 2527-2527.	0.6	4
103	Initial Outpatient Treatment of Venous Thromboembolism with Fondaparinux (Arixtra®): The Matisse Trials Blood, 2004, 104, 705-705.	0.6	4
104	An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients. Blood, 2017, 130, 626-626.	0.6	4
105	Plasma D-Dimer and Venous Thromboembolic Disease. , 0, , 85-111.		3
106	Management of Venous Thromboembolism in Pregnancy. , 0, , 353-371.		3
107	Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. European Thyroid Journal, 2016, 5, 139-144.	1.2	3
108	The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis. Blood, 2017, 130, 627-627.	0.6	3

#	Article	IF	CITATIONS
109	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. Thrombosis and Haemostasis, 2021, 0, .	1.8	3
110	Profile of antiphospholipid antibodies in HIVâ€infected and HIVâ€uninfected women with a history of thrombosis. International Journal of Laboratory Hematology, 2022, 44, 635-642.	0.7	3
111	A review of studies of the activation of the blood coagulation mechanism in chimpanzees ( <i>Pan) Tj ETQq1 1 0.</i>	784314 rg 0.3	gBT2/Overlock
112	A higher international normalized ratio may be better for your patient. Cmaj, 2008, 179, 217-217.	0.9	2
113	Management of Venous Thromboembolic Disease in Childhood. , 0, , 373-404.		2
114	Causes of Venous Thrombosis. , 0, , 1-26.		2
115	Followâ€up to comment on "Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: Systematic Review and Metaâ€Analysis― Journal of Thrombosis and Haemostasis, 2019, 17, 1007-1009.	1.9	2
116	von Willebrand factor propeptideâ€ŧoâ€entigen ratio in HIVâ€infected pregnancy: Evidence of endothelial activation. Journal of Thrombosis and Haemostasis, 2021, 19, 3168-3176.	1.9	2
117	Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study) Blood, 2009, 114, 488-488.	0.6	2
118	Initial and Long-Term Treatment of Deep Vein Thrombosis. , 0, , 473-485.		1
119	Management of Suspected Chronic Thromboembolic Pulmonary Hypertension. , 0, , 405-420.		1
120	Clinical Presentation of Pulmonary Embolism. , 0, , 61-69.		1
121	Clinical Presentation of Deep Vein Thrombosis. , 0, , 53-60.		1
122	Pulmonary Angiography: Technique, Indications and Complications. , 0, , 221-246.		1
123	A New Microparticle Coagulant Activity Assay to Predict Venous Thromboembolism in Patients with Pancreatic Cancer. Blood, 2014, 124, 4250-4250.	0.6	1
124	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Blood, 2016, 128, 2611-2611.	0.6	1
125	Effectiveness of Management of Suspected Deep Vein Thrombosis in General Practice Based on a Clinical Decision Rule Including a Point of Care D-dimer Test Blood, 2007, 110, 967-967.	0.6	1
126	Hyperthyroidism as a Risk Factor for Venous Thromboembolism: A Case-Control Study. Blood, 2008, 112, 5350-5350.	0.6	1

HARRY R Büller

HARRY R Büller

#	Article	IF	CITATIONS
127	Confirmation of the Failure of Computerized Impedance Plethysmography in the Diagnostic Management of Patients with Clinically Suspected Deep-Vein Thrombosis. Thrombosis and Haemostasis, 1991, 66, 744-744.	1.8	1
128	Unsuspected Pulmonary Embolism in Cancer Patients: A Multicenter, International, Prospective, Observational Study. Blood, 2014, 124, 1546-1546.	0.6	1
129	Introduction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2005, 34, 1-1.	0.5	Ο
130	Interventional Techniques for Venous Thrombosis. , 0, , 539-551.		0
131	Surgical Intervention in the Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension. , 0, , 513-537.		Ο
132	Echocardiography in Pulmonary Embolism. , 0, , 247-261.		0
133	Vena Cava Filters and Venous Thromboembolism. , 0, , 463-471.		0
134	Initial and Long-Term Treatment of Patients with Pulmonary Embolism. , 0, , 487-501.		0
135	Lung Scintigraphy. , 0, , 135-169.		0
136	MRI and MRA of the Pulmonary Vasculature. , 0, , 171-219.		0
137	Computed Tomography for Thromboembolic Disease. , 0, , 113-133.		Ο
138	Mechanical Prevention of Venous Thromboembolism. , 0, , 421-434.		0
139	Ultrasonography of Deep Vein Thrombosis. , 0, , 263-278.		Ο
140	Thrombolysis for the Treatment of Pulmonary Embolism. , 0, , 503-512.		0
141	The Natural History of Venous Thromboembolism. , 0, , 27-52.		Ο
142	Diagnostic Management Strategies in Patients with Suspected Deep Vein Thrombosis. , 0, , 315-327.		0
143	Clinical Prediction Rules for Diagnosis of Venous Thromboembolism. , 0, , 71-84.		0
144	Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients. JAMA Internal Medicine, 2015, 175, 1871.	2.6	0

#	Article	IF	CITATIONS
145	A Reduced Capacity To Generate Activated Protein C and the Role of PAI-1 Deficiency on Coagulation Activation and Fibrin Formation during Murine Influenza Pneumonia Blood, 2005, 106, 2134-2134.	0.6	0
146	International guidelines for antithrombotics in cancer patients Journal of Clinical Oncology, 2012, 30, e13062-e13062.	0.8	0
147	The Performance of the Original and Simplified Wells Scores in Combination with Age-Adjusted D-Dimer Testing in the Diagnostic Management of Pulmonary Embolism. Blood, 2016, 128, 2569-2569.	0.6	0
148	Interpreting Results in Clinical Research: Overview of Measures of Effect, Measures of Precision, and Measures of Diagnostic Accuracy for Clinicians and Researchers. , 0, , 15-22.		0